A Randomised, Double Blind Study Comparing Fixed Doses of 0.25mg, 0.5mg and 0.75mg Pramipexole to Investigate the Efficacy and Safety in Patients With Idiopathic Restless Legs Syndrome for 6 Weeks, Followed by 46 Weeks Open Label Long Term Study to Investigate the Safety and Efficacy of Pramipexole

Trial Profile

A Randomised, Double Blind Study Comparing Fixed Doses of 0.25mg, 0.5mg and 0.75mg Pramipexole to Investigate the Efficacy and Safety in Patients With Idiopathic Restless Legs Syndrome for 6 Weeks, Followed by 46 Weeks Open Label Long Term Study to Investigate the Safety and Efficacy of Pramipexole

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 08 Aug 2009 Status changed from active, no longer recruiting to completed.
    • 11 Jun 2009 Results preseneted at the 13th International Congress of Parkinson's Disease and Movement Disorders
    • 11 Jun 2009 Status change from active, no longer recruiting to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top